Jan 15 (Reuters) - AbbVie (ABBV.N), opens new tab plans to "commit less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on ...
Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...
(Reuters) - AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses related to milestone payments as well as research-and ...
In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer ...
AbbVie on Monday said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie said tavapadon met the primary ...
AbbVie has a solid medium-term growth plan and the means to accomplish it. Acquisitions and licensing deals could make for unexpected upsides. Still, its shares aren't priced inexpensively at the ...
AbbVie, a global pharmaceutical company headquartered in North Chicago, is acquiring Madison-based Nimble Therapeutics for $200 million in cash, the companies said in a news release. AbbVie has ...
19 analysts have expressed a variety of opinions on AbbVie ABBV over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback